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Edited by Veli-Pekka LehtoAbstract Diastolic heart failure (DHF) was produced in 6-day-
old piglets by intravenous administration of Doxorubicin, and
ANKRD1 protein and mRNA levels were determined in atrial
(A) and ventricular (V) chambers of failing vs control hearts.
In controls, ANKRD1 showed a left–right (L–R) asymmetric
distribution with protein levels 2-fold higher in the LA as com-
pared to the RA, and 8-fold higher in the LV than the RV. In
failing hearts, ANKRD1 levels were augmented about 2-fold in
each ventricle but equally reduced in both atria as compared to
controls. ANKRD1 downregulation in atria is discussed as a
process associated with advanced DHF.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The cardiac ankyrin repeat domain 1 protein (ANKRD1),
an early marker of cardiac cell diﬀerentiation, is expressed at
high levels in fetal, neonatal and adult heart [1–3]. As a result
of the work of many investigators, there is increasing evidence
to suspect an involvement of ANKRD1 in a broad range of
cardiac muscle disorders, including heart failure (HF). Accord-
ingly, ANKRD1 has been identiﬁed as a gene that is strongly
upregulated in left ventricle (LV)-myocardium in both animal
models [3–6] and patients [7,8] at HF secondary to various car-
diomyopathic conditions. Although the results as reported are
insuﬃcient to causally link the induction of ANKRD1 to the
decreased contractility of LV myocardium in vivo, they do
point to a potentially important role of ANKRD1 in down-
stream events associated with LV-myocardium response to
HF conditions [8,9].Abbreviations: ANKRD1, ankyrin repeat domain 1 protein; HF, heart
failure; DHF, diastolic heart failure; LA, left atrium; RA, right atrium;
LV, left ventricle; RV, right ventricle; Dox, doxorubicin; CO, cardiac
output; GEDV, global end-diastolic volume; EVLW, extravascular
lung water; ESP, end-systolic pressure; EDP, end-diastolic pressure;
CASQ2, calsequestrin 2; BNP, brain natriuretic peptide; RPL19,
ribosomal protein L19
*Corresponding author. Fax: + 34 981 138 714.
E-mail address: margot@udc.es (A.T. Mikhailov).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.06.073HF is often considered to be a consequence of decreased
contractility and/or reduced ejection fraction of the LV. How-
ever, a large number of patients with HF symptoms have a pre-
served systolic function but abnormal diastolic function, a
syndrome which is deﬁned as diastolic heart failure (DHF)
[10–13]. Recent clinical evaluations highlight the important
role of the left atrium (LA) in pathogenesis of DHF [14,15].
To the best of our knowledge, cardiac ANKRD1 expression
has not yet been studied at DHF. Moreover, alterations in
the ANKRD1 protein distribution in atrial chambers in re-
sponse to HF-conditions have not been analyzed in detail
[7,16] and have received no further consideration.
The goals of our experiments, therefore, were to develop a
DHF-like model in neonatal piglets and to determine a ﬁnger-
print of ANKRD1 gene expression throughout the heart,
accounting for region- and disease-speciﬁc aspects. We have
previously shown a diﬀerential response of pig neonatal heart
to increasing doses of cardiotoxic antibiotic, Doxorubicin
(Dox) [3]. In the present work, neonatal piglets exposed to a
single dose (1.5 mg/kg) of Dox developed a biventricular dia-
stolic dysfunction resulting in DHF. In failing hearts,
ANKRD1 protein and transcript content was signiﬁcantly
augmented in ventricles, but reduced in atria. Taken together,
the results strongly suggest that: (1) distinct ANKRD1 regula-
tory programs are operative in ventricular and atrial myocar-
dium at DHF; and (2) ANKRD1 downregulation in atria is
a diﬀerential sign of DHF, since acute systolic dysfunction re-
sulted in ANKRD1 upregulation in both atria and ventricles.2. Materials and methods
2.1. Animals and experimental procedures
All experimental procedures were carried out in accordance with the
European Commission Directive 86/609/EEC on the protection of ani-
mals used for experimental andother scientiﬁcpurposes. Six-day-oldpig-
lets were randomized in two groups assigned to receive a single i.v.
injection of isotonic saline (PBS) or 1.5 mg/kg of Dox (Sigma) as de-
scribed in [3]. On day 24 after injection, cardiac output (CO), global
end-diastolic volume (GEDV), and extravascular lung water (EVLW)
weremonitored in close-chest piglets byPiCCOdevice (PulsionAG,Ger-
many) in accordance with the manufacturer’s recommendations. The
measurements of ventricular end-systolic (LV/RVESP) and end-diastolic
pressure (LV/RVEDP)wereperformed inopen-chest piglets using aDra¨-
gerUM3.1pressure transducer anda recordingdevice (Dra¨gerwerkAG,
Germany) as described in [17]. Then piglets were euthanized to harvest
cardiac tissue for measurement of heart weight, LV/RV free wall thick-
ness, LA size, and for RNA and protein isolation, and ﬁxation [3,18].
Endocardial samples with or without Purkinje cells were isolated from
the LV of control piglets under a Nikon SMZ-2 Tmicroscope (Fig. 1G).blished by Elsevier B.V. All rights reserved.
Fig. 1. ANKRD1 expression in four cardiac chambers of control piglets. A and B, Western blot (WB) analysis of ANKRD1 protein levels in atria
and ventricles, respectively. C, D and E, F, ANKRD1 immunoreactivity (blue staining) on LA and LV sections, respectively. ed, endocardium; pc,
Purkinje cells; m, myocardium. Bar: C,E 68 lm; D,F 17 lm. G, sampling of LV endocardium (ed), Purkinje cell-containing endocardium (ed + pc),
and myocardium (m). H, ANKRD1 levels in ed, ed + pc, and m. I, Northern blot hybridization signals for ANKRD1, and control of RNA loading.
J, K, qPCR analysis of ANKRD1 mRNA levels (normalized to the internal standard RPL19) in ventricles and atria, respectively.CT, cycle threshold;
FT, ﬂuorescence threshold. *P < 0.05.
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Table 1





Number of animals 12 12
Heart/body ratio, ·1000 6.6 ± 0.3 6.4 ± 0.2
LV free wall thickness (mm) 9.7 ± 0.5 11.1 ± 0.5
RV free wall thickness (mm) 2.7 ± 0.7 3.8 ± 0.6
*
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SDS–polyacrylamide gel electrophoresis and quantitative Western
immunoblotting were performed as described in [3,19] using recombi-
nant full-length porcine ANKRD1 as a standard. Brieﬂy, snap-frozen
cardiac-tissue samples were pulverized and lysed in 2· SDS-sample
buﬀer (10 ll/mg of frozen powder) supplemented with complete prote-
ase inhibitor cocktail (Roche). Resulting extracts (range of 0.2–8 lg of
total protein) were SDS-electrophoresed and transferred to PVDF
membrane (Hybond-P, Amersham Biosciences). The replicas were
incubated with rabbit anti-pig ANKRD1 antibodies [3] and detected
using HPR-conjugated anti-rabbit IgG (Sigma) and the Super-Signal
West Pico chemiluminescent substrate (Pierce Biotechnology) accord-
ing to the manufacturer’s instructions. The blots were re-probed with
anti-canine cardiac calsequestrin 2 (CASQ2) antibodies (Abcam) as
an additional control for loading. Quantiﬁcation of Western blots
was obtained by using a Bio-Rad GS700 densitometer with Quantity
One software.
2.3. Immunohistochemistry
Immunodetection of ANKRD1 on paraformaldehyde-ﬁxed, paraf-
ﬁn-embedded sections was performed as described in [18]. Serial sec-
tions of control and failing heart tissues were incubated with primary
rabbit anti-ANKRD1 immuno-aﬃnity puriﬁed antibodies. Then the
sections were assayed using the Vectastain ABC-AP kit (Vector Labo-
ratories) in accordance with the manufacturer’s recommendations and
counterstained with nuclear fast red. Substitution of the primary anti-
bodies with anti-ANKRD1 antibodies pre-adsorbed by puriﬁed full-
length porcine ANKRD1 was included in negative controls.
2.4. Northern blot
Total RNA was isolated from snap-frozen cardiac samples using
RNeasyMidi columns (Qiagen) according to the manufacturer’s proto-
col. RNA (5 lg/run) was separated by 1.2% formaldehyde–agarose gel
electrophoresis and transferred to a nylonHybond-Nmembrane (Amer-
sham Biosciences). The pig ANKRD1 full-length coding sequence la-
beled with [a-32P]dCTP was used as a probe. Blots were prehybridized,
hybridized, washed, and developed as described previously [3].
2.5. Real-time quantitative reverse transcription-polymerase chain
reaction (qPCR)
Two-step qPCR [20] was performed on a Bio-Rad IQ5 detection sys-
tem with SYBR Green mix. Non-template and non-RT RNA template
reactions were used as negative controls. Primers for each porcine gene
located in diﬀerent exons were as follows: ANKRD1 (207-50-TAG-
AAGCTGGAGCCCAGATTG-3 0 and 208-50-GCAACTTATCCC-
GAGCACTGA-3 0), brain natriuretic peptide (BNP: 82-5 0-GCTCCT
GCTCCTGTTCTTGCA-30 and 251-5 0- GGTCCAGCAGCTCCTG-
TATC-3 0), ribosomal protein L19 (RPL19: 64-5 0-CTGCTCAGAA-
GATACCGTGAAT-3 0 and 206-50-GCTTGTGGATGTGCTCCAT
GA-3 0). RPL19 was used as an internal standard, because its expres-
sion was not diﬀerent throughout cardiac chambers nor between con-
trol and Dox-treated hearts [3,21]. Each primer pair used yielded a
single peak of dissociation on the melting curve and a single band with
the expected size on agarose gel. Identity of the PCR products was
conﬁrmed by sequencing. All reactions were run in duplicate in at least
two independent experiments. Normalized gene expression analyses
were performed with Bio-Rad IQ5 software.
2.6. Statistics
The data are presented as means ± S.E.M. Comparisons were made
using paired Student’s t-test. Probability values of P < 0.05 were con-
sidered statistically signiﬁcant.LV end-systolic pressure (mm Hg) 80.6 ± 5.1 67.1 ± 3.3
LV end-diastolic pressure (mm Hg) 3.8 ± 1.1 8.5 ± 1.3*
RV end-systolic pressure (mm Hg) 18.0 ± 1.3 16.9 ± 0.9
RV end-diastolic pressure (mm Hg) 3.3 ± 1.0 6.1 ± 1.1*
Cardiac output index (L/min/m2) 3.4 ± 0.4 3.4 ± 0.6
Extravascular lung water (ml/kg) 57.2 ± 8.4 101.3 ± 31.5*
LV BNP mRNA, relative value 1.0 ± 0.1 5.1 ± 0.3*
RV BNP mRNA, relative value 1.0 ± 0.2 6.3 ± 0.5*
LA BNP mRNA, relative value 1.0 ± 0.2 1.3 ± 0.4
RA BNP mRNA, relative value 1.0 ± 0.3 2.4 ± 0.6*
*P < 0.05.3. Results
3.1. Dox-injected neonatal piglets develop the features of human
DHF
Ventricular-chamber performance in vivo and cardiac mor-
phology ex vivo were analyzed in piglets 24 days after Dox
administration (Table 1). LV/RVESP was slightly lower,whereas LV/RVEDP (an accepted marker for ventricular com-
pliance) was signiﬁcantly higher in Dox-injected compared to
PBS-injected piglets. These ﬁndings are further corroborated
by pulmonary congestion (elevated EVLW indexes) indicating
severe diastolic dysfunction (with preserved CO) in DHF-pig-
lets. Failing hearts displayed little change in LV/RV free-wall
thickness. In Dox-injected piglets, BNP (an accepted cardiac
stretch response marker) mRNA levels increased in both ven-
tricles and in the RA, remaining unchanged in the LA.
3.2. ANKRD1 displays left vs right and atrial vs ventricular
expression patterns in sham piglets
In sham piglets, ANKRD1 showed a striking asymmetric
L–R distribution with protein levels 2-fold higher in the LA
as compared to the RA, and protein content enriched 8-fold
in the LV over the RV (Figs. 1A and B). The ANKRD1
mRNA expression was coincidently enhanced 2-fold in the
LA vs RA while only 3-fold higher in the LV as compared
to the RV (Figs. 1J and K). Further, ANKRD1 protein and
mRNA were more abundant in the LA vs LV and in the RA
vs RV as revealed by Western blot and Northern blot hybrid-
ization, respectively (Figs. 1I and 2E, control).
In both LA and RA, ANKRD1 immunoreactivity was pre-
dominantly expressed throughout the entire atrial myocardium
and was low or undetectable in endo- and epicardial layers
(Figs. 1C and D). We were the ﬁrst to demonstrate the locali-
zation of ANKRD1 in ventricular Purkinje cells [18]. In this
work, immunohistochemical analysis yielded strong ANKRD1
signals in ventricular Purkinje cells and, though to a less ex-
tent, also in working myocytes (Figs. 1E and F). As revealed
by Western blot, the ANKRD1 protein content in the Purkinje
cell-containing samples was about 2-fold higher as compared
to that in subjacent working myocytes (Figs. 1G and H).
3.3. ANKRD1 shows opposite patterns at DHF being
upregulated in ventricles and downregulated in atria
In DHF hearts, the ANKRD1 protein content was signiﬁ-
cantly augmented in both LV (2.3 ± 0.4-fold vs sham) and
RV (3.1 ± 0.5-fold vs sham), but reduced in the LA
(0.4 ± 0.1-fold vs sham) and RA (0.5 ± 0.1-fold vs sham)
(Fig. 2A–D). In contrast to ANKRD1, levels of the MLC2a,
cardiac a-actin, b-myosin heavy chain, were found to be simi-
Fig. 2. ANKRD1 expression in four cardiac chambers of Dox-injected vs control piglets. A, B, C, and D, Western blot analysis of ANKRD1 protein
levels in LA, RA, LV, and RV, respectively. CASQ2 – internal control of protein loading. E, Western blot analysis comparing ANKRD1 expression
levels in four cardiac chambers of control vs 1.5 mg/kg Dox-injected piglets. F, Western blot analysis of ANKRD1 levels in the LA and RA of
control and 4 mg/kg Dox-injected piglets. G, qPCR analysis of ANKRD1 mRNA levels (normalized to RPL19) in LA, RA, LV, and RV of control
and Dox-injected piglets. *P < 0.05.
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examination revealed a stronger ANKRD1 immunostaining
of working myocytes in failing ventricles, whereas failing atrial
myocardium staining was weaker as compared to respective
tissue-sections in controls (not shown).
Dox-induced DHF led to upregulation of mRNA transcripts
for ANKRD1 in both LV and RV to an extent similar to that
of ANKRD1 protein enrichment in each failing ventricle (i.e.,
about 2-fold vs sham; see Fig. 2G). However, in the failing
atrial myocardium, whereas ANKRD1 protein was downregu-
lated in both atria, the ANKRD1 mRNA was downregulated
in the LA (2.1 ± 0.5-fold vs sham) but insigniﬁcantly reduced
in the RA (Fig. 2G). It is possible that in DHF hearts the
ANKRD1 protein is translated with a lower eﬃciency in the
RA as compared to the LA.
Thus, in our model of DHF-like syndrome the ANKRD1
protein concentration equally increased in both ventricles,
whereas in both atria its concentration showed a sharp reduc-
tion. Owing to these opposite expression kinetics, the normal
LA-predominant pattern of ANKRD1 distribution was con-
versely changed to a LV-predominant one in failing hearts
(Fig. 2E).
To determine whether ANKRD1 downregulation in atria
was an advanced event of DHF and not a consequence of
unspeciﬁc Dox eﬀects, we screened ANKRD1 distribution
in atria of neonatal piglets that received a dose of Dox
(i.e., 4.0 mg/kg) about 3-fold higher than that used in the
present work. Dox, at a dose of 4 mg/kg, caused the rapid
development of LV myocardial dysfunction and acute systolic
HF accompanied by a marked ANKRD1 and BNP upregu-
lation in both ventricles [3]. Western blot analysis demon-
strated that in these animals ANKRD1 was dramatically
upregulated in both failing atria, in sharp contrast to its
downregulation in atrial myocardium in our model of DHF
(Fig. 2F).4. Discussion
Utilizing a newly developed model of DHF-like syndrome in
neonatal piglets, this study examines, for the ﬁrst time, the
relationship between changes in expression of the ANKRD1
gene in four cardiac chambers and pathophysiological abnor-
malities of ventricular/atrial functions. In humans with
DHF, LV relaxation is impaired, which increases LV and
LA diastolic pressure which, in turn, results in elevated LA
myocardium tension that culminates in enlarged LA. Accord-
ingly, LA size/volume is considered a predictive ‘‘morphologic
expression’’ marker of DHF [13,22]. We show here that
ANKRD1 is downregulated in the LA of DHF piglets at both
the protein and mRNA level. To the best of our knowledge,
this is the ﬁrst report that implicates ANKRD1 as a possible
molecular predictor of advanced atrial dysfunction at experi-
mental DHF.
Why ANKRD1 is downregulated in atria and what conse-
quences such downregulation at DHF might have are not
clear. Initially, ANKRD1 was isolated as a cardio-restricted
binding partner of YB-1 (ubiquitous transcription factor),
and so ANKRD1 was implicated in the negative regulation
of muscle gene expression [1,23]. Thereafter, ANKRD1 was
identiﬁed as a binding partner of sarcomeric proteins, myopall-
adin [24] and titin [25] suggesting a role of ANKRD1 in sarco-meric integrity and myoﬁbrillar stretch sensing, respectively.
More recently, ANKRD1 has also been shown to interact with
cardiac CASQ2 [18], desmin, and itself [26]. This in vitro data
indicates that ANKRD1 may be a multifaceted adaptor poly-
peptide capable of binding various muscle-associated proteins,
and accordingly ANKRD1 could be simultaneously implicated
in diverse processes in the cardiomyocyte that adds an addi-
tional layer of complexity to the study of ANKRD1 functions
in vivo.
Further, as shown in this work, the normal postnatal heart is
characterized by clear regional diﬀerences in ANKRD1 expres-
sion, such as L vs R and A vs V. This is consistent with our
previous work demonstrating a similar ANKRD1 mRNA
and protein ﬁngerprint in the heart of newborn piglets [3]. If
postnatal ANKRD1 expression is chamber-dependent, then
one would expect that altering its expression in response to
cardiac insults could be, at least in part, chamber-speciﬁc
[3,7]. Under our experimental conditions, the ANKRD1 pro-
tein content was equally augmented in both ventricles but
equally decreased in both atria indicating, therefore, a diﬀerent
A–V response of postnatal myocardium to Dox-induced DHF.
Of note, in spite of this opposite A–V response, the asymmetric
L vs R pattern of ANKRD1 expression persisted in failing
hearts.
HF can result from predominant LV, RV or biventricular
dysfunction, and cardiac regional ANKRD1 expression may
be aﬀected to a diﬀerent degree depending on pathophysiolog-
ical states [3,7]. In our DHF-like model, elevated LV/RVEDP
could lead to a state of biventricular myocardium stretch until
the ventricles become so stiﬀ that the easily distensible thin-
walled atrial myocardium fails to increase diastolic ﬁlling pres-
sure. At advanced stages, chronic stretch of the ventricular
muscle ﬁbers can result in signiﬁcant ANKRD1 upregulation
in each ventricle [25,27,28], whereas an imbalance between
the increase in contractile demand (due to excessive atrial pres-
sure) and the contractile capacity of atrial myocytes [13] might
provoke ANKRD1 downregulation in atria.
Insight into ANKRD1 downregulation might come from
studies on in vitro cultivated heart-derived myocytes exposed
to oxidative stress-inducing agents (including Dox). Such
agents downregulate ANKRD1 expression probably via
induced overexpression of the proapoptotic transcriptional
factor, GADD153 [29]. However, in our experiments Dox
application (1.5 mg/kg) led to signiﬁcant ANKRD1 upregula-
tion in both ventricles. Moreover, at higher Dox-doses (4 mg/
kg) ANKRD1 was upregulated in both ventricles [3] and at-
ria (this work). Taken together, the results strongly suggest
that the opposite A-V ANKRD1 expression kinetics at exper-
imental DHF are associated with diﬀerent functional altera-
tions of ventricular and atrial myocardium rather than with
hypothetical diﬀerences in the sensitivity of A and V myo-
cytes to a single Dox-exposure in vivo. Decreased ANKRD1
levels in atria could be considered as a diﬀerential sign of dia-
stolic dysfunction, because acute systolic HF was shown to be
associated with gene upregulation in both atria (Fig. 2F) and
ventricles.
With regard to demonstrated biventricular ANKRD1
upregulation at porcine DHF, it is interesting to note that
adenoviral-mediated overexpression of ANKRD1 in neonatal
rat ventricular myocytes in vitro resulted in decreased contrac-
tile responsiveness of infected cells to catecholamine or calcium
overloads [9].
M. Torrado et al. / FEBS Letters 580 (2006) 4182–4187 4187In conclusion, the ANKRD1 expression mapping presented
here provides the ﬁrst framework for further and more detailed
analysis of normal and pathological regulation of the gene in
the four-chambered postnatal heart. At present, our ﬁndings
demonstrate that the DHF-like syndrome is related to reduced
ANKRD1 expression in atria (speciﬁcally in the LA) and
opposite gene upregulation in ventricles.
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